Long-term Outcomes of Gastroenteropancreatic Neuroendocrine Tumors

Weiwei Chi, Richard R.P. Warner, David L. Chan, Simron Singh, Eva Segelov, Jonathan Strosberg, Juan Wisnivesky, Michelle K. Kim

Research output: Contribution to journalArticleResearchpeer-review

10 Citations (Scopus)

Abstract

Objectives Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare but have been increasing in incidence. Limited data on the long-term outcomes of patients with these tumors are available. Methods In this study, we used population-based data from the National Cancer Institute to assess long-term disease-specific survival (DSS) of patients who have undergone surgery for nonmetastatic disease. All patients with NETs of the stomach, small intestine, colon, rectum, appendix, and pancreas diagnosed between 1988 and 2009 were identified from the Surveillance, Epidemiology and End Results registry. Staging was derived from Surveillance, Epidemiology and End Results data using the European Neuroendocrine Tumor Society guidelines. Cases with incomplete staging data were excluded, along with those with stage IV disease, or those who did not undergo surgical resection. Results Kaplan-Meier analyses were constructed to determine DSS. Analyses were further stratified according to tumor site, stage at diagnosis, and tumor grade. Overall, 13,348 patients with GEP-NETs meeting the inclusion criteria were identified. Conclusions There were excellent outcomes for most GEP-NET patients, with a 20-year DSS of greater than 75% across all sites and stages. Pancreatic tumors had the worst outcomes, but DSS remains greater than 50% at 20 years.

Original languageEnglish
Pages (from-to)321-325
Number of pages5
JournalPancreas
Volume47
Issue number3
DOIs
Publication statusPublished - 1 Mar 2018

Keywords

  • Gastrointestinal tract
  • Neuroendocrine tumor
  • Pancreas

Cite this

Chi, W., Warner, R. R. P., Chan, D. L., Singh, S., Segelov, E., Strosberg, J., ... Kim, M. K. (2018). Long-term Outcomes of Gastroenteropancreatic Neuroendocrine Tumors. Pancreas, 47(3), 321-325. https://doi.org/10.1097/MPA.0000000000001005
Chi, Weiwei ; Warner, Richard R.P. ; Chan, David L. ; Singh, Simron ; Segelov, Eva ; Strosberg, Jonathan ; Wisnivesky, Juan ; Kim, Michelle K. / Long-term Outcomes of Gastroenteropancreatic Neuroendocrine Tumors. In: Pancreas. 2018 ; Vol. 47, No. 3. pp. 321-325.
@article{7eb61cf3c85146dc8721aebd505dcfa1,
title = "Long-term Outcomes of Gastroenteropancreatic Neuroendocrine Tumors",
abstract = "Objectives Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare but have been increasing in incidence. Limited data on the long-term outcomes of patients with these tumors are available. Methods In this study, we used population-based data from the National Cancer Institute to assess long-term disease-specific survival (DSS) of patients who have undergone surgery for nonmetastatic disease. All patients with NETs of the stomach, small intestine, colon, rectum, appendix, and pancreas diagnosed between 1988 and 2009 were identified from the Surveillance, Epidemiology and End Results registry. Staging was derived from Surveillance, Epidemiology and End Results data using the European Neuroendocrine Tumor Society guidelines. Cases with incomplete staging data were excluded, along with those with stage IV disease, or those who did not undergo surgical resection. Results Kaplan-Meier analyses were constructed to determine DSS. Analyses were further stratified according to tumor site, stage at diagnosis, and tumor grade. Overall, 13,348 patients with GEP-NETs meeting the inclusion criteria were identified. Conclusions There were excellent outcomes for most GEP-NET patients, with a 20-year DSS of greater than 75{\%} across all sites and stages. Pancreatic tumors had the worst outcomes, but DSS remains greater than 50{\%} at 20 years.",
keywords = "Gastrointestinal tract, Neuroendocrine tumor, Pancreas",
author = "Weiwei Chi and Warner, {Richard R.P.} and Chan, {David L.} and Simron Singh and Eva Segelov and Jonathan Strosberg and Juan Wisnivesky and Kim, {Michelle K.}",
year = "2018",
month = "3",
day = "1",
doi = "10.1097/MPA.0000000000001005",
language = "English",
volume = "47",
pages = "321--325",
journal = "Pancreas",
issn = "0885-3177",
publisher = "Ovid Technologies (Wolters Kluwer) - Lippincott Williams & Wilkins",
number = "3",

}

Chi, W, Warner, RRP, Chan, DL, Singh, S, Segelov, E, Strosberg, J, Wisnivesky, J & Kim, MK 2018, 'Long-term Outcomes of Gastroenteropancreatic Neuroendocrine Tumors', Pancreas, vol. 47, no. 3, pp. 321-325. https://doi.org/10.1097/MPA.0000000000001005

Long-term Outcomes of Gastroenteropancreatic Neuroendocrine Tumors. / Chi, Weiwei; Warner, Richard R.P.; Chan, David L.; Singh, Simron; Segelov, Eva; Strosberg, Jonathan; Wisnivesky, Juan; Kim, Michelle K.

In: Pancreas, Vol. 47, No. 3, 01.03.2018, p. 321-325.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Long-term Outcomes of Gastroenteropancreatic Neuroendocrine Tumors

AU - Chi, Weiwei

AU - Warner, Richard R.P.

AU - Chan, David L.

AU - Singh, Simron

AU - Segelov, Eva

AU - Strosberg, Jonathan

AU - Wisnivesky, Juan

AU - Kim, Michelle K.

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Objectives Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare but have been increasing in incidence. Limited data on the long-term outcomes of patients with these tumors are available. Methods In this study, we used population-based data from the National Cancer Institute to assess long-term disease-specific survival (DSS) of patients who have undergone surgery for nonmetastatic disease. All patients with NETs of the stomach, small intestine, colon, rectum, appendix, and pancreas diagnosed between 1988 and 2009 were identified from the Surveillance, Epidemiology and End Results registry. Staging was derived from Surveillance, Epidemiology and End Results data using the European Neuroendocrine Tumor Society guidelines. Cases with incomplete staging data were excluded, along with those with stage IV disease, or those who did not undergo surgical resection. Results Kaplan-Meier analyses were constructed to determine DSS. Analyses were further stratified according to tumor site, stage at diagnosis, and tumor grade. Overall, 13,348 patients with GEP-NETs meeting the inclusion criteria were identified. Conclusions There were excellent outcomes for most GEP-NET patients, with a 20-year DSS of greater than 75% across all sites and stages. Pancreatic tumors had the worst outcomes, but DSS remains greater than 50% at 20 years.

AB - Objectives Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare but have been increasing in incidence. Limited data on the long-term outcomes of patients with these tumors are available. Methods In this study, we used population-based data from the National Cancer Institute to assess long-term disease-specific survival (DSS) of patients who have undergone surgery for nonmetastatic disease. All patients with NETs of the stomach, small intestine, colon, rectum, appendix, and pancreas diagnosed between 1988 and 2009 were identified from the Surveillance, Epidemiology and End Results registry. Staging was derived from Surveillance, Epidemiology and End Results data using the European Neuroendocrine Tumor Society guidelines. Cases with incomplete staging data were excluded, along with those with stage IV disease, or those who did not undergo surgical resection. Results Kaplan-Meier analyses were constructed to determine DSS. Analyses were further stratified according to tumor site, stage at diagnosis, and tumor grade. Overall, 13,348 patients with GEP-NETs meeting the inclusion criteria were identified. Conclusions There were excellent outcomes for most GEP-NET patients, with a 20-year DSS of greater than 75% across all sites and stages. Pancreatic tumors had the worst outcomes, but DSS remains greater than 50% at 20 years.

KW - Gastrointestinal tract

KW - Neuroendocrine tumor

KW - Pancreas

UR - http://www.scopus.com/inward/record.url?scp=85042550967&partnerID=8YFLogxK

U2 - 10.1097/MPA.0000000000001005

DO - 10.1097/MPA.0000000000001005

M3 - Article

VL - 47

SP - 321

EP - 325

JO - Pancreas

JF - Pancreas

SN - 0885-3177

IS - 3

ER -

Chi W, Warner RRP, Chan DL, Singh S, Segelov E, Strosberg J et al. Long-term Outcomes of Gastroenteropancreatic Neuroendocrine Tumors. Pancreas. 2018 Mar 1;47(3):321-325. https://doi.org/10.1097/MPA.0000000000001005